NYSE: RMDResmed Inc Stock
$213.82-3.02 (-1.39%)
Updated May 10, 2024
RMD Price
$213.82
Fair Value Price
N/A
Market Cap
$31.41B
52 Week Low
$132.24
52 Week High
$232.99
P/E
32.79x
P/B
6.78x
P/S
6.35x
PEG
2.45x
Dividend Yield
0.9%
Revenue
$4.58B
Earnings
$958.38M
Gross Margin
55.8%
Operating Margin
27.02%
Profit Margin
20.9%
Debt to Equity
0.47
Operating Cash Flow
$1B
Beta
0.95
Next Earnings
May 14, 2024
Ex-Dividend
May 8, 2024
Next Dividend
Jun 13, 2024
RMD Overview
ResMed Inc. manufactures medical equipment for the diagnosis, treatment and management of sleep-disordered breathing, sleep apnea, and chronic obstructive pulmonary disease. Offerings include continuous positive airway pressure devices, auto-bilevel devices, variable positive airway pressure devices, automatic positive airway pressure devices, humidifiers, ventilation products, masks, headgear, and data/patient management products. The comany serves sleep clinics, home healthcare dealers, and third party payers. ResMed was founded in 1989 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RMD scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RMD ($213.82) is trading above its intrinsic value of $66.28, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RMD is poor value based on its earnings relative to its share price (32.79x), compared to the US market average (30.02x)
P/E vs Market Valuation
RMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more RMD due diligence checks available for Premium users.
Be the first to know about important RMD news, forecast changes, insider trades & much more!
RMD News
Valuation
RMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
32.79x
Industry
58.36x
Market
30.02x
RMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RMD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
RMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.78x
Industry
3.57x
RMD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RMD price to earnings growth (PEG)
For valuing profitable companies with growth potential
RMD is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
RMD's financial health
Profit margin
Revenue
$1.2B
Net Income
$300.5M
Profit Margin
25.1%
RMD's Earnings (EBIT) of $1.24B... subscribe to Premium to read more.
Interest Coverage Financials
RMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.8B
Liabilities
$2.2B
Debt to equity
0.47
RMD's short-term assets ($2.35B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RMD's short-term assets ($2.35B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$402.0M
Investing
-$33.2M
Financing
-$335.9M
RMD's operating cash flow ($1.20B)... subscribe to Premium to read more.
Debt Coverage Financials
RMD vs Medical Stocks
Resmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.